Height/length and weight, vital signs including pulse, blood pressure, and mean arterial pressure taken during open label and blinded study drug periods, and pulse and blood pressure within 30 minutes
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease.
Supplemental Material for "Risk of Infections During Treatment with Oral Janus Kinase Inhibitors in Randomized Placebo-Controlled Trials: A Systematic Review and Meta-Analysis" published in JAAD Inter